Drug cuts breast cancer risk for some post-menopausal women
|
|
( Ben Edwards / Getty Images ) Exemestane, sold as Aromasin, can reduce the risk of tumors in high- and moderate-risk post-menopausal women by 65% over a three-year period, researchers reported June 4 in the New England Journal of Medicine. Aromasin, a drug already used to treat breast cancer, does not appear to have the potentially lethal side effects associated with two anti-estrogen drugs (tamoxifen and raloxifene--sold as Evista) already approved for reducing breast tumor risk in health women. |
E-mail
Twitter
Facebook
Read This Later
Comments are filtered for language and registration is required. The Times makes no guarantee of comments' factual accuracy. Readers may report inappropriate comments by clicking the Report Abuse link next to a comment. Here are the full legal terms you agree to by using this comment form.
L.A. for less than the price of sunblock. 
Currently there are no comments. Be the first to comment!